Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088612 | 0.86 | NPC1 (0.48) | NPC1RAB9AALDH1A1KDM4EGAA | |
| SCHEMBL653980 | 0.85 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNABDKRB1 | |
| SCHEMBL655164 | 0.85 | AURKA (0.42) | NPC1RAB9AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL650318 | 0.85 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNABDKRB1 | |
| SCHEMBL2913699 | 0.84 | GPR35 (0.51) | NPC1RAB9AALDH1A1KDM4EPOLB | |
| SCHEMBL2904998 | 0.84 | GPR35 (0.47) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL13211583 | 0.84 | KDM4E (0.37) | RAB9AALDH1A1KDM4EHSD17B10GAA | |
| SCHEMBL4083540 | 0.84 | FGFR1 (0.50) | NPC1RAB9AJAK2JAK1 | |
| SCHEMBL653285 | 0.84 | DYRK1A (0.41) | NPC1RAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4091966 | 0.83 | GPR35 (0.54) | NPC1RAB9AALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119641-B2 | 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-21 | — | — | US | disclosed |
| EP-2051981-B1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-08-25 | — | — | EP | disclosed |
| US-20090239924-A1 | 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-2051981-A1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-04-29 | — | — | EP | disclosed |
| WO-2007138017-A1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239924-A1 | 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | IGF1R, CDK1, CDK15 | NPC1 1674/4885RAB9A 1901/4885ALDH1A1 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.